학술논문
SARS-CoV-2 and Aspergillussection Fumigaticoinfection in an immunocompetent patient treated with corticosteroids
Document Type
Article
Author
Source
Revista Iberoamericana de Micología; January-March 2021, Vol. 38 Issue: 1 p16-18, 3p
Subject
Language
ISSN
11301406
Abstract
Patients with severe viral pneumonia are likely to receive high-dose immunomodulatory drugs to prevent clinical worsening. Aspergillusspecies have been described as frequent secondary pneumonia agents in severely ill influenza patients receiving steroids. COVID-19 patients admitted to Intensive Care Unit (ICU) are receiving steroids as part of their treatment and they share clinical characteristics with other patients with severe viral pneumonias. COVID-19 patients receiving steroids should be considered a putative risk group of invasive aspergillosis.